Issue 7, 2018

Design, synthesis and bioactivity investigation of tetrandrine derivatives as potential anti-cancer agents

Abstract

Twenty-four 14-sulfonamide–tetrandrine derivatives as potential anti-cancer agents were synthesized. The synthetic derivatives were investigated for their cytotoxic activity against human cancer cell lines MDA-MB-231, PC3, WM9, HEL and K562. Initially, the IC50 values (50% inhibitory concentrations) of all of the compounds were determined. These derivatives exhibited potent, but distinct, inhibitory effects on the above-mentioned cell lines. Among them, compound 23, which was modified with a 2-naphthalenesulfonyl group at the 14-amino position, showed impressive inhibition of all five cancer cell lines, and especially of MDA-MB-231 cells with an IC50 value of 1.18 ± 0.14 μM. Further mechanism exploration showed that 23 induced potent apoptotic cell death on MDA-MB-231 cancer cells in a concentration-dependent manner. The results revealed that 23 might be a potential anti-cancer drug candidate.

Graphical abstract: Design, synthesis and bioactivity investigation of tetrandrine derivatives as potential anti-cancer agents

Supplementary files

Article information

Article type
Research Article
Submitted
05 Mar 2018
Accepted
24 Apr 2018
First published
04 May 2018

Med. Chem. Commun., 2018,9, 1131-1141

Design, synthesis and bioactivity investigation of tetrandrine derivatives as potential anti-cancer agents

J. Song, J. Lan, C. Chen, S. Hu, J. Song, W. Liu, X. Zeng, H. Lou, Y. Ben-David and W. Pan, Med. Chem. Commun., 2018, 9, 1131 DOI: 10.1039/C8MD00125A

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Spotlight

Advertisements